It shares a similar structure to Gefitinib and Erlotinib, which are both FDA-approved EGFR specific tyrosine kinase inhibitors that are under clinical trials for HNSCC [15] (Available online: http://clinicaltrials.gov). Here, EGFR is linked to head and neck squamous cell carcinoma.